ARTICLE | Company News
FDA approves plazomicin for cUTI, but not blood infections
June 26, 2018 3:30 PM UTC
Achaogen Inc. (NASDAQ:AKAO) said FDA approved Zemdri plazomicin to treat complicated urinary tract infections (cUTIs), but issued a complete response letter for the same candidate to treat bloodstream infections. The mixed decision is in line with the outcome of a May FDA advisory committee meeting.
Achaogen shares sank $2.43 (20%) to $9.59 on the news Tuesday...
BCIQ Company Profiles